Prostate Cancer Clinical Trials in Philadelphia

Showing 201-220 of 387 trials

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275

Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Metastatic Castration-resistant Prostate Cancer

Tceleron Therapeutics, Inc.16 participantsStarted Nov 2019

Tampa, Florida, United States • Kansas City, Kansas, United States • St Louis, Missouri, United States +6 more locations

COMPLETEDPhase 2< 1 mile

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005847

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which treatment regimen is more effective in treating metastatic prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy with that of chemotherapy plus biological therapy in treating patients who have progressive or metastatic prostate cancer that has not responded to hormone therapy.

Prostate Cancer

Eastern Cooperative Oncology GroupStarted Apr 2001

Denver, Colorado, United States • Atlanta, Georgia, United States • Decatur, Georgia, United States +16 more locations

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer Trials in Other Cities

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Improving Decision-Making for Low Health Literate Prostate CA Patients

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

A Study of FT-7051 in Men With MCRPC

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

Other Conditions in Philadelphia